Across eight independent cohorts, our model not only demonstrated an independent predictive performance after adjusting features like age, gender, AJCC stage, grade, intravesical therapy, systemic chemotherapy, smoking, BCG treatment, platinum therapy, neoadjuvant chemotherapy, FGFR3, p53, RAS, and RB1 mutations but also presented remarkable superior accuracy in assessing the prognosis risk according to the C‐index assessment, suggesting that it potentially to be a promising surrogate to evaluate the prognosis risk for BLCA in clinical practice. This evidence concerns the gene FGFR3 and bladder transitional cell carcinoma.